Scott Harkonen may have thought he could move on.

Fifteen months ago, the Department of Justice signed a deferred prosecution agreement with InterMune, the company Harkonen once led. Some former employees of the Brisbane, Calif.-based biotech had engaged in illegal off-label marketing of its osteoporosis drug Actimune, the company acknowledged.